<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02440789</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5337</org_study_id>
    <secondary_id>2UM1AI068636</secondary_id>
    <nct_id>NCT02440789</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)</brief_title>
  <official_title>Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to find out about the safety of sirolimus in individuals with
      HIV infection who were also being treated with ART. The investigators wanted to learn whether
      sirolimus decreases inflammation and immune activation in the body; whether sirolimus changes
      the level of HIV in the participants' blood; and how sirolimus interacts with ART in the
      blood. Sirolimus is approved by the Food and Drug Administration (FDA) to prevent organ
      rejection in patients aged 13 years and older receiving kidney transplants. Sirolimus had
      also been used for the prevention of complications after stem cell transplants and as a
      treatment for certain kinds of cancers in HIV-infected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was conducted with an initial lead-in period of 12 weeks where participants
      remained on ART, without study intervention. Samples were collected to define the
      pre-intervention steady-state of HIV, inflammation and immune activation parameters.

      At week 12, sirolimus therapy was initiated for the planned 20 weeks of treatment. In order
      to achieve therapeutic levels, sirolimus therapy was initiated with lead-in dose of 0.025 or
      0.05 mg/kg/day, depending on the ART regimen. Doses for each participant were then adjusted,
      based on trough blood sirolimus concentrations, to achieve target concentrations between 5
      and 10 ng/mL. There were frequent initial visits for sirolimus trough concentration
      monitoring and potential dose adjustments, at weeks 12.5, 13, 13.5, 14, 14.5, 15, 15.5 and
      16. Then visits occurred at weeks 18, 20, 24, 28 and 32. After the week 32 visit, the planned
      end of study treatment, there was an additional 12 weeks of post-sirolimus follow-up, with a
      final visit at week 44.

      Study visits included physical examinations, clinical assessments, safety monitoring, and
      blood and oral swab collection. Anal swabs were collected at week 12 and 32. Samples were
      stored for subsequent protocol testing for the study outcomes.

      In the primary analysis, the significance level was 0.05 for all analyses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2015</start_date>
  <completion_date type="Actual">February 1, 2018</completion_date>
  <primary_completion_date type="Actual">November 2, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Met the Study-defined Composite Safety Endpoint</measure>
    <time_frame>Screening to study week 32 (week 20 of Sirolimus)</time_frame>
    <description>The study-defined primary safety endpoint was a composite endpoint. A participant was considered to have met the endpoint if the participant 1) experienced a new Grade â‰¥3 Adverse Event (AE), including signs/symptoms, lab toxicity or clinical event, that was definitely, probably or possibly related to study treatment, as judged by the core team, or 2) had a change in CD4+ cell count ( confirmed &gt;50% decline or to &lt;300 cells/mm3) while on sirolimus. The screening visit occurred within 60 days of study entry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - Immunologic: Frequency of HIV-1 Gag-specific CD8+ T-cells by Intracellular Staining for IFN-gamma</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Frequency of HIV-1 Gag-specific CD8+ T-cells by intracellular staining for IFN-gamma. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - Immunologic: Change in HIV-1 Gag-specific CD8+ T-cells by Intracellular Staining for IFN-gamma</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in HIV-1 Gag-specific CD8+ T-cells by intracellular staining for IFN-gamma (week 32 measurement minus baseline measurement)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - Virologic: CD4+ T-cell-associated HIV-1 RNA</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>CD4+ T-cell-associated HIV-1 RNA. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - Virologic: Change in CD4+ T-cell-associated HIV-1 RNA</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in CD4+ T-cell-associated HIV-1 RNA (week 32 measurement minus baseline measurement)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - Virologic: Plasma HIV-1 RNA by SCA</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Plasma HIV-1 RNA by SCA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - Virologic: Change in Plasma HIV-1 RNA by SCA</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in plasma HIV-1 RNA by SCA (week 32 measurement minus baseline measurement).
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of CD4+ T-cell Counts</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>CD4+ T-cell counts. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ T-cell Counts</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in CD4+ T-cell counts (week 32 measurement minus baseline measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-1 RNA Levels</measure>
    <time_frame>weeks 0, 12, (pre-Sirolimus) 16, 24, 32 (4, 12, 20 weeks on Sirolimus) and 44</time_frame>
    <description>HIV-1 RNA levels by conventional assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-associated HIV-1 DNA Levels in Total CD4+ Cells</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>HIV-1 DNA levels in CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cell-associated HIV-1 DNA Levels in Total CD4+ Cells</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in HIV-1 DNA levels in CD4+ T-cells (week 32 measurement minus baseline measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-1 Gag-specific CD107a+ CD8+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Frequency of HIV-1 Gag-specific CD107a+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1 Gag-specific CD107a+ CD8+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in frequency of HIV-1 Gag-specific CD107a+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-1 Gag-specific CD40L+ CD8+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Frequency of HIV-1 Gag-specific CD40L+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1 Gag-specific CD40L+ CD8+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in frequency of HIV-1 Gag-specific CD40L+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-1 Gag-specific IL-2+ CD8+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Frequency of HIV-1 Gag-specific IL-2+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1 Gag-specific IL-2+ CD8+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in frequency of HIV-1 Gag-specific IL-2+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-1 Gag-specific MIP1B+ CD8+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Frequency of HIV-1 Gag-specific MIP1B+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1 Gag-specific MIP1B+ CD8+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in frequency of HIV-1 Gag-specific MIP1B+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Frequency of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1 Gag-specific TNF-alpha+ CD8+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in frequency of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-1 Gag-specific CD4+ T-cell by Intracellular Staining for IFN-gamma Responses</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Frequency of HIV-1 Gag-specific CD4+ T-cells by intracellular staining for IFN-gamma. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1 Gag-specific CD4+ T-cell by Intracellular Staining for IFN-gamma Responses</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in HIV-1 Gag-specific CD4+ T-cells by intracellular staining for IFN-gamma (week 32 measurement minus baseline measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-1 Gag-specific CD107a+ CD4+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Frequency of HIV-1 Gag-specific CD107a+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1 Gag-specific CD107a+ CD4+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in frequency of HIV-1 Gag-specific CD107a+ CD4+ T-cells (week 32 measurement minus baseline measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-1 Gag-specific CD40L+ CD4+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Frequency of HIV-1 Gag-specific CD40L+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1 Gag-specific CD40L+ CD4+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in frequency of HIV-1 Gag-specific CD40L+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-1 Gag-specific IL-2+ CD4+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Frequency of HIV-1 Gag-specific IL-2+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1 Gag-specific IL-2+ CD4+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in frequency of HIV-1 Gag-specific IL-2+ CD4+ T-cells (week 32 measurement minus baseline measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-1 Gag-specific MIP1B+ CD4+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Frequency of HIV-1 Gag-specific MIP1B+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1 Gag-specific MIP1B+ CD4+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in frequency of HIV-1 Gag-specific MIP1B+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Frequency of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1 Gag-specific TNF-alpha+ CD4+ T-cell Responses</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in frequency of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of %CD69+ CD4+ T-cells</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Measurement of %CD69+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in of %CD69+ CD4+ T-cells</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in of %CD69+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of %CD69+ CD8+ T-cells</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Measurement of %CD69+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in of %CD69+ CD8+ T-cells</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in of %CD69+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of %Ki67+ CD4+ T-cells</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Measurement of %Ki67+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in of %Ki67+ CD4+ T-cells</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in of %Ki67+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of %Ki67+ CD8+ T-cells</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Measurement of %Ki67+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in of %Ki67+ CD8+ T-cells</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in of %Ki67+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of %PD1+ CD4+ T-cells</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Measurement of %PD1+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in of %PD1+ CD4+ T-cells</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in of %PD1+ CD4+ T-cells (week 32 measurement minus baseline measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of %PD1+ CD8+ T-cells</measure>
    <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
    <description>Measurement of %PD1+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in of %PD1+ CD8+ T-cells</measure>
    <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
    <description>Change in of %PD1+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <arm_group_label>Sirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection

          -  On continuous ART for â‰¥24 months prior to study entry.

          -  CD4+ cell count â‰¥350 cells/mm^3

          -  Plasma HIV-1 RNA below the level of quantification for â‰¥24 months.

          -  White blood cell (WBC) â‰¥3000/mm^3

          -  Platelet count â‰¥125,000/mm^3

          -  Absolute neutrophil count (ANC) &gt;1300/mm^3

          -  Aspartate aminotransferase (AST) &lt;1.25 x upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) &lt;1.25 x ULN

          -  Calculated creatinine clearance (CrCl) â‰¥60 mL/min

          -  Fasting or non-fasting triglyceride level â‰¤350 mg/dL

          -  Fasting or non-fasting LDL &lt;160 mg/dL

          -  Urine protein to urine creatinine ratio â‰¤1 g/g from random urine collection

        Exclusion Criteria:

          -  Serious illness requiring systemic treatment and/or hospitalization

          -  Documentation of any CDC Category C AIDS-indicator condition or oropharyngeal
             candidiasis (thrush)

          -  Intended modification of ART during the study.

          -  Latent tuberculosis (TB) infection

          -  TB disease within 48 weeks prior to study entry requiring treatment.

          -  History of active hepatitis B (HBV) infection.

          -  Hepatitis C virus (HCV) RNA-positive

          -  Previous myelodysplasia syndrome, lymphoproliferative disease, lung disease,
             malignancies, congestive heart failure, life-threatening fungal infection or
             herpes-zoster/varicella-zoster viral infection requiring treatment.

          -  Detectable Epstein-Barr virus (EBV) in blood

          -  Active infection other than HIV that required receipt of systemic antibiotic therapy
             by intravenous infusion

          -  History of major hypersensitivity reaction to macrolide drugs including angioedema,
             anaphylaxis, drug-induced dermatitis, or hypersensitivity vasculitis.

          -  Currently pregnant or breastfeeding, or planning to become pregnant prior to or during
             the study.

          -  Use of immunomodulators (eg, interleukins, interferons, and cyclosporine), HIV
             vaccine, systemic cytotoxic chemotherapy, or investigational therapy.

          -  Active drug or alcohol use or dependence

          -  Vaccination within 14 days prior to study entry.

          -  On or planned to change to a PI-based ART or cobicistat-boosted regimen

          -  Anti-human papillomavirus (HPV) therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Henrich, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Priscilla Hsue, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>801 University of California, San Francisco HIV/AIDS CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whitman Walker Health CRS (31791)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Miami AIDS CRS (901)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center CRS (5802)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University CRS (2101)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Uptown CRS (7803)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>31787 University of Rochester Adult HIV Therapeutic Strategies Network CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS (2401)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston AIDS Research Team CRS (31473)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS (1401)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rsc.niaid.nih.gov/</url>
    <description>DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 2.0, November 2014</description>
  </link>
  <link>
    <url>https://rsc.niaid.nih.gov/</url>
    <description>Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual) Version 2.0 January 2010</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <results_first_submitted>December 12, 2019</results_first_submitted>
  <results_first_submitted_qc>December 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 30, 2019</results_first_posted>
  <disposition_first_submitted>September 10, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>September 10, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 18, 2018</disposition_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02440789/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02440789/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at 10 Clinical Research Sites (CRSs) in the United States between December 2015 and March 2017.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sirolimus</title>
          <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Initiated Sirolimus</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 20 Weeks of Sirolimus</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not willing to adhere to reqs</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who initiated Sirolimus</population>
      <group_list>
        <group group_id="B1">
          <title>Sirolimus</title>
          <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.
Sirolimus</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Safety Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="46" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White Non-Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black Non-Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4+ T-cell counts</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="818" lower_limit="635" upper_limit="1031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 Gag-specific CD8+ T-cells by intracellular staining for interferon (IFN)-gamma</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%Gag-specific IFN-gamma+ CD8+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.1" lower_limit="0.05" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4+ T-cell-associated HIV-1 RNA</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus</population>
          <units>log10(copies/10^6 CD4+ T-cells)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.57" lower_limit="2.19" upper_limit="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA by single-copy assay (SCA)</title>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Study Entry</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 0.7 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 0.7 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 0.7 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 0.7 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA</title>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Study Entry</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 Gag-specific CD4+ T-cells by intracellular staining for IFN-gamma</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%Gag-specific IFN-gamma+ CD4+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GAG-specific CD107a+ CD8+ T-Cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%Gag-specific CD107a+ CD8+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.01" lower_limit="0" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GAG-specific CD107a+ CD4+ T-Cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%Gag-specific CD107a+ CD4+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="0" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GAG-specific CD40L+ CD8+ T-Cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%Gag-specific CD40L+CD8+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.01" lower_limit="0" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GAG-specific CD40L+ CD4+ T-Cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%Gag-specific CD40L+CD4+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.09" lower_limit="0.05" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GAG-specific interleukin (IL)-2+ CD8+ T-Cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%Gag-specific IL-2+ CD8+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.01" lower_limit="0" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GAG-specific IL-2+ CD4+ T-Cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%Gag-specific IL-2+ CD4+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.02" lower_limit="0.01" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GAG-specific MIP1B+ CD8+ T-Cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%Gag-specific MIP1B+ CD8+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.06" lower_limit="0.03" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GAG-specific MIP1B+ CD4+ T-Cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%Gag-specific MIP1B+ CD4+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.01" lower_limit="0" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GAG-specific tumor necrosis factor (TNF)-alpha+ CD8+ T-Cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%Gag-specific TNF-alpha CD8+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.03" lower_limit="0.02" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GAG-specific TNF-alpha+ CD4+ T-Cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%Gag-specific TNF-alpha CD4+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.03" lower_limit="0.02" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>%CD69+ CD4+ T-cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%CD69+ CD4+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" lower_limit="4.5" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>%CD69+ CD8+ T-cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%CD69+ CD8+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.4" lower_limit="7.2" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>%Ki67+ CD4+ T-cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%Ki67+ CD4+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" lower_limit="1.9" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>%Ki67+ CD8+ T-cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%Ki67+ CD8+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" lower_limit="1.4" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>% programmed cell death protein 1 (PD1)+ CD4+ T-cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%PD1+ CD4+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.7" lower_limit="31.3" upper_limit="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>%PD1+ CD8+ T-cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>%PD1+ CD8+ T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" lower_limit="21" upper_limit="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 DNA levels in CD4+ T-cells</title>
          <description>Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>n = 16 participants completed 20 weeks of Sirolimus.</population>
          <units>log10(copies/10^6 CD4+ T-cells)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.72" lower_limit="2.08" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Met the Study-defined Composite Safety Endpoint</title>
        <description>The study-defined primary safety endpoint was a composite endpoint. A participant was considered to have met the endpoint if the participant 1) experienced a new Grade â‰¥3 Adverse Event (AE), including signs/symptoms, lab toxicity or clinical event, that was definitely, probably or possibly related to study treatment, as judged by the core team, or 2) had a change in CD4+ cell count ( confirmed &gt;50% decline or to &lt;300 cells/mm3) while on sirolimus. The screening visit occurred within 60 days of study entry.</description>
        <time_frame>Screening to study week 32 (week 20 of Sirolimus)</time_frame>
        <population>Participants Initiating Sirolimus.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Met the Study-defined Composite Safety Endpoint</title>
          <description>The study-defined primary safety endpoint was a composite endpoint. A participant was considered to have met the endpoint if the participant 1) experienced a new Grade â‰¥3 Adverse Event (AE), including signs/symptoms, lab toxicity or clinical event, that was definitely, probably or possibly related to study treatment, as judged by the core team, or 2) had a change in CD4+ cell count ( confirmed &gt;50% decline or to &lt;300 cells/mm3) while on sirolimus. The screening visit occurred within 60 days of study entry.</description>
          <population>Participants Initiating Sirolimus.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy - Immunologic: Frequency of HIV-1 Gag-specific CD8+ T-cells by Intracellular Staining for IFN-gamma</title>
        <description>Frequency of HIV-1 Gag-specific CD8+ T-cells by intracellular staining for IFN-gamma. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Immunologic: Frequency of HIV-1 Gag-specific CD8+ T-cells by Intracellular Staining for IFN-gamma</title>
          <description>Frequency of HIV-1 Gag-specific CD8+ T-cells by intracellular staining for IFN-gamma. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific IFN-gamma+ CD8+ T-cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 on Sirolimus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy - Immunologic: Change in HIV-1 Gag-specific CD8+ T-cells by Intracellular Staining for IFN-gamma</title>
        <description>Change in HIV-1 Gag-specific CD8+ T-cells by intracellular staining for IFN-gamma (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Immunologic: Change in HIV-1 Gag-specific CD8+ T-cells by Intracellular Staining for IFN-gamma</title>
          <description>Change in HIV-1 Gag-specific CD8+ T-cells by intracellular staining for IFN-gamma (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific IFN-gamma+ CD8+ T-cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy - Virologic: CD4+ T-cell-associated HIV-1 RNA</title>
        <description>CD4+ T-cell-associated HIV-1 RNA. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Virologic: CD4+ T-cell-associated HIV-1 RNA</title>
          <description>CD4+ T-cell-associated HIV-1 RNA. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>log10(copies/10^6 CD4+ T-cells)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 on Sirolimus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy - Virologic: Change in CD4+ T-cell-associated HIV-1 RNA</title>
        <description>Change in CD4+ T-cell-associated HIV-1 RNA (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Virologic: Change in CD4+ T-cell-associated HIV-1 RNA</title>
          <description>Change in CD4+ T-cell-associated HIV-1 RNA (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>log10(copies/10^6 CD4+ T-cells)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy - Virologic: Plasma HIV-1 RNA by SCA</title>
        <description>Plasma HIV-1 RNA by SCA</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Virologic: Plasma HIV-1 RNA by SCA</title>
          <description>Plasma HIV-1 RNA by SCA</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study week 0</title>
              <category_list>
                <category>
                  <title>&lt; 0.7 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 0.7 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 12</title>
              <category_list>
                <category>
                  <title>&lt; 0.7 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 0.7 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <category_list>
                <category>
                  <title>&lt; 0.7 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 0.7 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy - Virologic: Change in Plasma HIV-1 RNA by SCA</title>
        <description>Change in plasma HIV-1 RNA by SCA (week 32 measurement minus baseline measurement).
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Virologic: Change in Plasma HIV-1 RNA by SCA</title>
          <description>Change in plasma HIV-1 RNA by SCA (week 32 measurement minus baseline measurement).
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>log10(copies/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test; results less than the analysis lower limit (0.7 cp/mL) were imputed to a value of one half the analysis lower limit.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of CD4+ T-cell Counts</title>
        <description>CD4+ T-cell counts. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of CD4+ T-cell Counts</title>
          <description>CD4+ T-cell counts. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="937" spread="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="858" spread="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="820" spread="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="820" spread="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="891" spread="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4+ T-cell Counts</title>
        <description>Change in CD4+ T-cell counts (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4+ T-cell Counts</title>
          <description>Change in CD4+ T-cell counts (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-118" spread="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of HIV-1 RNA Levels</title>
        <description>HIV-1 RNA levels by conventional assay</description>
        <time_frame>weeks 0, 12, (pre-Sirolimus) 16, 24, 32 (4, 12, 20 weeks on Sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of HIV-1 RNA Levels</title>
          <description>HIV-1 RNA levels by conventional assay</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Week 0</title>
              <category_list>
                <category>
                  <title>&lt; 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 12</title>
              <category_list>
                <category>
                  <title>&lt; 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 16 (Week 4 on Sirolimus)</title>
              <category_list>
                <category>
                  <title>&lt; 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 24 (Week 12 on Sirolimus)</title>
              <category_list>
                <category>
                  <title>&lt; 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 32 (Week 20 on Sirolimus)</title>
              <category_list>
                <category>
                  <title>&lt; 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 44</title>
              <category_list>
                <category>
                  <title>&lt; 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 40 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-associated HIV-1 DNA Levels in Total CD4+ Cells</title>
        <description>HIV-1 DNA levels in CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Cell-associated HIV-1 DNA Levels in Total CD4+ Cells</title>
          <description>HIV-1 DNA levels in CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>log10(copies/10^6 CD4+ T-cells)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cell-associated HIV-1 DNA Levels in Total CD4+ Cells</title>
        <description>Change in HIV-1 DNA levels in CD4+ T-cells (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cell-associated HIV-1 DNA Levels in Total CD4+ Cells</title>
          <description>Change in HIV-1 DNA levels in CD4+ T-cells (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>log10(copies/10^6 CD4+ T-cells)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of HIV-1 Gag-specific CD107a+ CD8+ T-cell Responses</title>
        <description>Frequency of HIV-1 Gag-specific CD107a+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of HIV-1 Gag-specific CD107a+ CD8+ T-cell Responses</title>
          <description>Frequency of HIV-1 Gag-specific CD107a+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%Gag-specific CD107a+ CD8+ T-cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV-1 Gag-specific CD107a+ CD8+ T-cell Responses</title>
        <description>Change in frequency of HIV-1 Gag-specific CD107a+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV-1 Gag-specific CD107a+ CD8+ T-cell Responses</title>
          <description>Change in frequency of HIV-1 Gag-specific CD107a+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%Gag-specific CD107a+ CD8+ T-cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of HIV-1 Gag-specific CD40L+ CD8+ T-cell Responses</title>
        <description>Frequency of HIV-1 Gag-specific CD40L+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of HIV-1 Gag-specific CD40L+ CD8+ T-cell Responses</title>
          <description>Frequency of HIV-1 Gag-specific CD40L+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%Gag-specific CD40L+ CD8+ T-cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV-1 Gag-specific CD40L+ CD8+ T-cell Responses</title>
        <description>Change in frequency of HIV-1 Gag-specific CD40L+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV-1 Gag-specific CD40L+ CD8+ T-cell Responses</title>
          <description>Change in frequency of HIV-1 Gag-specific CD40L+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%Gag-specific CD40L+ CD8+ T-cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of HIV-1 Gag-specific IL-2+ CD8+ T-cell Responses</title>
        <description>Frequency of HIV-1 Gag-specific IL-2+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of HIV-1 Gag-specific IL-2+ CD8+ T-cell Responses</title>
          <description>Frequency of HIV-1 Gag-specific IL-2+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%Gag-specific IL-2+ CD8+ T-cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV-1 Gag-specific IL-2+ CD8+ T-cell Responses</title>
        <description>Change in frequency of HIV-1 Gag-specific IL-2+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV-1 Gag-specific IL-2+ CD8+ T-cell Responses</title>
          <description>Change in frequency of HIV-1 Gag-specific IL-2+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%Gag-specific IL-2+ CD8+ T-cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of HIV-1 Gag-specific MIP1B+ CD8+ T-cell Responses</title>
        <description>Frequency of HIV-1 Gag-specific MIP1B+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of HIV-1 Gag-specific MIP1B+ CD8+ T-cell Responses</title>
          <description>Frequency of HIV-1 Gag-specific MIP1B+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific MIP1B+ CD8+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV-1 Gag-specific MIP1B+ CD8+ T-cell Responses</title>
        <description>Change in frequency of HIV-1 Gag-specific MIP1B+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV-1 Gag-specific MIP1B+ CD8+ T-cell Responses</title>
          <description>Change in frequency of HIV-1 Gag-specific MIP1B+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific MIP1B+ CD8+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cell Responses</title>
        <description>Frequency of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cell Responses</title>
          <description>Frequency of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific TNF-a+ CD8+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV-1 Gag-specific TNF-alpha+ CD8+ T-cell Responses</title>
        <description>Change in frequency of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV-1 Gag-specific TNF-alpha+ CD8+ T-cell Responses</title>
          <description>Change in frequency of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific TNF-a+ CD8+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of HIV-1 Gag-specific CD4+ T-cell by Intracellular Staining for IFN-gamma Responses</title>
        <description>Frequency of HIV-1 Gag-specific CD4+ T-cells by intracellular staining for IFN-gamma. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of HIV-1 Gag-specific CD4+ T-cell by Intracellular Staining for IFN-gamma Responses</title>
          <description>Frequency of HIV-1 Gag-specific CD4+ T-cells by intracellular staining for IFN-gamma. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific IFN-g+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV-1 Gag-specific CD4+ T-cell by Intracellular Staining for IFN-gamma Responses</title>
        <description>Change in HIV-1 Gag-specific CD4+ T-cells by intracellular staining for IFN-gamma (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV-1 Gag-specific CD4+ T-cell by Intracellular Staining for IFN-gamma Responses</title>
          <description>Change in HIV-1 Gag-specific CD4+ T-cells by intracellular staining for IFN-gamma (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific IFN-g+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of HIV-1 Gag-specific CD107a+ CD4+ T-cell Responses</title>
        <description>Frequency of HIV-1 Gag-specific CD107a+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of HIV-1 Gag-specific CD107a+ CD4+ T-cell Responses</title>
          <description>Frequency of HIV-1 Gag-specific CD107a+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific CD107a+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV-1 Gag-specific CD107a+ CD4+ T-cell Responses</title>
        <description>Change in frequency of HIV-1 Gag-specific CD107a+ CD4+ T-cells (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV-1 Gag-specific CD107a+ CD4+ T-cell Responses</title>
          <description>Change in frequency of HIV-1 Gag-specific CD107a+ CD4+ T-cells (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific CD107a+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of HIV-1 Gag-specific CD40L+ CD4+ T-cell Responses</title>
        <description>Frequency of HIV-1 Gag-specific CD40L+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of HIV-1 Gag-specific CD40L+ CD4+ T-cell Responses</title>
          <description>Frequency of HIV-1 Gag-specific CD40L+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific CD40L+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV-1 Gag-specific CD40L+ CD4+ T-cell Responses</title>
        <description>Change in frequency of HIV-1 Gag-specific CD40L+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV-1 Gag-specific CD40L+ CD4+ T-cell Responses</title>
          <description>Change in frequency of HIV-1 Gag-specific CD40L+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific CD40L+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of HIV-1 Gag-specific IL-2+ CD4+ T-cell Responses</title>
        <description>Frequency of HIV-1 Gag-specific IL-2+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of HIV-1 Gag-specific IL-2+ CD4+ T-cell Responses</title>
          <description>Frequency of HIV-1 Gag-specific IL-2+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific IL-2+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV-1 Gag-specific IL-2+ CD4+ T-cell Responses</title>
        <description>Change in frequency of HIV-1 Gag-specific IL-2+ CD4+ T-cells (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV-1 Gag-specific IL-2+ CD4+ T-cell Responses</title>
          <description>Change in frequency of HIV-1 Gag-specific IL-2+ CD4+ T-cells (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific IL-2+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of HIV-1 Gag-specific MIP1B+ CD4+ T-cell Responses</title>
        <description>Frequency of HIV-1 Gag-specific MIP1B+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of HIV-1 Gag-specific MIP1B+ CD4+ T-cell Responses</title>
          <description>Frequency of HIV-1 Gag-specific MIP1B+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific MIP1B+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV-1 Gag-specific MIP1B+ CD4+ T-cell Responses</title>
        <description>Change in frequency of HIV-1 Gag-specific MIP1B+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV-1 Gag-specific MIP1B+ CD4+ T-cell Responses</title>
          <description>Change in frequency of HIV-1 Gag-specific MIP1B+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific MIP1B+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cell Responses</title>
        <description>Frequency of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cell Responses</title>
          <description>Frequency of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific TNF-alpha+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV-1 Gag-specific TNF-alpha+ CD4+ T-cell Responses</title>
        <description>Change in frequency of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV-1 Gag-specific TNF-alpha+ CD4+ T-cell Responses</title>
          <description>Change in frequency of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%GAG-specific TNF-alpha+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of %CD69+ CD4+ T-cells</title>
        <description>Measurement of %CD69+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of %CD69+ CD4+ T-cells</title>
          <description>Measurement of %CD69+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%CD69+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in of %CD69+ CD4+ T-cells</title>
        <description>Change in of %CD69+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in of %CD69+ CD4+ T-cells</title>
          <description>Change in of %CD69+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%CD69+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of %CD69+ CD8+ T-cells</title>
        <description>Measurement of %CD69+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of %CD69+ CD8+ T-cells</title>
          <description>Measurement of %CD69+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%CD69+ CD8+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in of %CD69+ CD8+ T-cells</title>
        <description>Change in of %CD69+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in of %CD69+ CD8+ T-cells</title>
          <description>Change in of %CD69+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%CD69+ CD8+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of %Ki67+ CD4+ T-cells</title>
        <description>Measurement of %Ki67+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of %Ki67+ CD4+ T-cells</title>
          <description>Measurement of %Ki67+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%Ki67+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in of %Ki67+ CD4+ T-cells</title>
        <description>Change in of %Ki67+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in of %Ki67+ CD4+ T-cells</title>
          <description>Change in of %Ki67+ CD4+ T-cells (week 32 measurement minus baseline measurement).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%Ki67+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of %Ki67+ CD8+ T-cells</title>
        <description>Measurement of %Ki67+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of %Ki67+ CD8+ T-cells</title>
          <description>Measurement of %Ki67+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%Ki67+ CD8+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in of %Ki67+ CD8+ T-cells</title>
        <description>Change in of %Ki67+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in of %Ki67+ CD8+ T-cells</title>
          <description>Change in of %Ki67+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%Ki67+ CD8+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of %PD1+ CD4+ T-cells</title>
        <description>Measurement of %PD1+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of %PD1+ CD4+ T-cells</title>
          <description>Measurement of %PD1+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%PD1+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in of %PD1+ CD4+ T-cells</title>
        <description>Change in of %PD1+ CD4+ T-cells (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in of %PD1+ CD4+ T-cells</title>
          <description>Change in of %PD1+ CD4+ T-cells (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%PD1+ CD4+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of %PD1+ CD8+ T-cells</title>
        <description>Measurement of %PD1+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
        <time_frame>At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of %PD1+ CD8+ T-cells</title>
          <description>Measurement of %PD1+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%PD1+ CD8+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 16 (week 4 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 24 (week 12 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 32 (week 20 on Sirolimus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in of %PD1+ CD8+ T-cells</title>
        <description>Change in of %PD1+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
        <time_frame>At study weeks 0, 12 and 32 (week 20 on Sirolimus)</time_frame>
        <population>Participants completing 20 weeks of Sirolimus</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in of %PD1+ CD8+ T-cells</title>
          <description>Change in of %PD1+ CD8+ T-cells (week 32 measurement minus baseline measurement)</description>
          <population>Participants completing 20 weeks of Sirolimus</population>
          <units>%PD1+ CD8+ T-Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.85" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Screening to study week 32 (week 20 of Sirolimus)</time_frame>
      <desc>At entry, all grades of signs and symptoms that occurred within 30 days before entry were recorded; post-entry, all grades of Grade â‰¥2 were recorded. All Grade 3 or higher sign/symptom, any sign/symptom regardless of grade that led to a change in study treatment, or that met ICH, EAE or SAE guidelines were recorded. The DAIDS AE Grading Table Version 2.0 and Expedited AE Manual Version 2.0 were used.
All participants exposed to Sirolimus are included.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sirolimus</title>
          <description>Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks. Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>ACTG Clinicaltrials.gov Coordinator</name_or_title>
      <organization>ACTG Network Coordinating Center, Social and Scientific Systems, Inc.</organization>
      <phone>(301) 628-3313</phone>
      <email>ACTGCT.Gov@s-3.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

